Skanska USA Commercial Development Inc. has secured a lease at 150 Second St. in Kendall Sq. with Foundation Medicine, Inc., a molecular information company that uses genomic analysis to help doctors identify targeted cancer treatments that might be best for each patient. Foundation Medicine expects to occupy 61,591 s/f beginning in September.
"We are thrilled to be welcoming a cutting-edge, pioneering company like Foundation Medicine as our anchor tenant at 150 Second St.," said Shawn Hurley, executive VP and regional manager of Skanska. "The demand we are seeing for highly sustainable office and lab space in Kendall Square is a strong indicator that Cambridge will continue to attract the world's leading biotechnology and life science companies, such as Foundation Medicine, and we look forward to witnessing the progress they will make in advancing cancer research in our building."
The site will house Foundation Medicine's clinical laboratory, which is CLIA certified and has received accreditation from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP), as well as the company's research laboratory and commercial offices.
150 Second St., which was completed in December 2012, is a lab and office building representing Skanska's first commercial development investment in Cambridge. Skanska acquired the property in November of 2010 and self-financed 100% of the development costs for the three-story class A project.
The building features 123,000 s/f of highly sustainable lab space and is on track to obtain LEED Gold Certification from the United States Green Building Council.
Jones Lang LaSalle is the brokerage firm representing Skanska USA and Richards Barry Joyce & Partners represents Foundation Medicine.